Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. März 2026 06:29 ET | Quelle: Research and Markets

Anticoagulants Market Competitive Analysis Report 2025: Key Players Analysis, Profiles, Product Developments, Mergers, Strategic Collaborations, and Revenue Forecast Insights to 2033

Dublin, March 09, 2026 (GLOBE NEWSWIRE) -- The "Anticoagulants Market Companies Analysis Key Players Analysis, Company Profiles, Product Developments, Mergers, Strategic Collaborations, and Revenue...
06. März 2026 09:33 ET | Quelle: Spherix Global Insights

Spherix Global Insights Finds Benlysta Exposure Expanding and Rheumatologists Increasingly Turning to Lupkynis in Lupus Nephritis

Exton, PA, March 06, 2026 (GLOBE NEWSWIRE) -- New findings from Spherix Global Insights’ Patient Chart Dynamix™: Lupus Nephritis (US), 2025 report reveal a treatment landscape in transition as...
05. März 2026 06:00 ET | Quelle: HUTCHMED (China) Limited

HUTCHMED Reports 2025 Full Year Results and Business Updates

— Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth — — $457 million net income, driven by profitable core operations and non-core disposal — —...
04. März 2026 08:30 ET | Quelle: CDT Equity Inc.

CDT Positions for Transformational Growth

CDT Positions for Transformational Growth
04. März 2026 07:30 ET | Quelle: NervGen Pharma Corp.

NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
04. März 2026 04:00 ET | Quelle: Octopus AIM VCT 2 plc

Final Results

Octopus AIM VCT 2 plcFinal Results Octopus AIM VCT 2 plc today announces the final results for the year ended 30 November 2025. Octopus AIM VCT 2 plc (the ‘Company’) is a Venture Capital Trust (VCT)...
03. März 2026 09:40 ET | Quelle: Research and Markets

7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Asthma - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The asthma market in the...
03. März 2026 09:32 ET | Quelle: Research and Markets

Prostate Cancer Market Competitive Landscape Report 2026: Comprehensive Insights About 230+ Companies and 265+ Drugs by Product Type, Stage, and Route of Administration

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Prostate Cancer - Competitive Landscape, 2026" report has been added to ResearchAndMarkets.com's offering.This "Prostate Cancer - Competitive...
03. März 2026 04:00 ET | Quelle: Quell TX

Quell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR-Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA Approval

London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating its autologous CAR-Treg therapy, QEL-005, in patients...
03. März 2026 03:59 ET | Quelle: Quell TX

Quell Therapeutics Demonstrates Safety, Phenotypic Stability, Durability and Early Efficacy with Phenotype‑Locked™ CAR‑Tregs in LIBERATE Phase 1/2 Liver Transplant Study

London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today...

Vorherige Seite

Nächste Seite